SES Orders Two State-of-the-Art Satellites for its Prime TV Neighbourhood Serving 118 Million Homes
18.11.2021 10:50:00 EET | Business Wire | Press release
SES announced today it has ordered two geostationary (GEO) Ku-band satellites for its prime orbital slot at 19.2 degrees East to maintain the premium services it provides to its European video customers and to capture new opportunities in the region. These two replacement satellites – ASTRA 1P and ASTRA 1Q – will be built by Thales Alenia Space, a joint venture between Thales (67%) and Leonardo (33%) and are expected to launch in 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211117006466/en/
SES Orders Two State-of-the-Art Satellites for its Prime TV Neighbourhood Serving 118 Million Homes (Photo: Business Wire)
ASTRA 1P, a classic wide-beam satellite, will support SES’s prime TV neighbourhood and enable content owners, private and public broadcasters across Germany, France and Spain to continue broadcasting satellite TV channels in the highest-picture quality in the most cost-efficient manner.
ASTRA 1Q, a next-generation digital satellite with both wide beams and high-throughput spot beams, will be able to support direct-to-home (DTH) operations like ASTRA 1P. In addition, the fully flexible ASTRA 1Q is customisable on orbit and can be deployed easily to other orbital positions, enabling SES to serve the dynamic needs of its video and data customers well into the future.
The current satellites operating at SES’s prime orbital neighbourhood of 19.2 degrees East serve an unparalleled 118 million households or over 43 percent of all European TV homes. Specifically the majority of satellite homes in Germany, France and Spain are being served by the ASTRA satellites. The number of TV homes receiving HD content from these satellites has increased almost 30 percent over the past five years.
“Our prime TV neighbourhood at 19.2 degrees East is one of our most valuable assets and has been key to enabling renowned European broadcasters to grow their TV audiences in the last 30 years. These two satellites will have the resiliency, reliability and redundancy that our video customers need, and will be able to deliver continued premium services well into 2040,” said Steve Collar, CEO of SES. “Additionally, thanks to advanced satellite technology, we will be future-proofing our investment and injecting a high degree of flexibility into ASTRA 1Q to ensure we are meeting the evolving needs of all the markets we serve.”
“This contract reflects the ability of Thales Alenia Space to match complementary customer’s needs for both capacity and flexibility. We are proud to offer to SES our full electric Spacebus NEO flight proven product line to answer Astra 1P mission as well as our innovative software defined solution Space Inspire, allowing Astra 1Q the full in-orbit flexibility requested to serve the dynamic of the evolving market,” said Hervé Derrey, CEO of Thales Alenia Space.
The procurement of the two satellites was already incorporated within SES's existing Capital Expenditure outlook for 2021-2025 and is fully compliant with the company’s financial policy.
Follow us on:
Twitter
Facebook
YouTube
LinkedIn
Instagram
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,500 channels and has an unparalleled reach of 361 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117006466/en/
Contact information
Suzanne Ong
Tel: +352 710 725 500
External Communications
suzanne.ong@ses.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
vVARDIS Announces Investment from Apollo —Achieves Unicorn Status27.4.2026 15:51:00 EEST | Press release
vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulations clinically proven to treat tooth decay. Curodont™ supports enamel repair by facilitating the formation of crystalline mineral structure throughout the affected area, giving dental professionals an easy-to-use, restorative opti
IAS Launches IAS Total TV Solutions Giving Marketers ‘Linear-like’ Transparency for Connected TV27.4.2026 15:30:00 EEST | Press release
Integral Ad Science (IAS) today announced ‘IAS Total TV’, a new comprehensive suite of Connected TV (CTV) solutions designed specifically to bring ‘linear-like’ transparency to streaming TV. IAS Total TV can provide marketers with genre, rating, language, show and program-level data in aggregate from Disney, NBCUniversal, Paramount and Prime Video, in addition to multiple opted-in publishers using Publica. IAS Total TV integrates content insights, media quality, supply path and outcomes into a unified view within the IAS Signal user interface (UI). Advertisers can determine when and how they want their advertising to run alongside CTV content, ensuring brand-related and brand suitable environments. “As advertisers continue to double down on connected TV, the need for greater visibility and performance insight has never been more important,” said Dana McGraw, SVP, Data and Measurement Science, Disney Advertising. “By collaborating with IAS, we’re helping provide advertisers with clearer
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-making. However, compared to Riskified’s agentic commerce pulse survey in Q4 2025, consumer sentiment has shifted, with growing concerns around fraud, security, and accountability slowing the path to fully autonomous, agent-driven transactions. Key findings from th
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 15:00:00 EEST | Press release
Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environment. The findings highlight a growing disconnect between ambition and execution. Cross-border transactions are expected to form a significant portion of deal pipelines, with 47% of respondents expecting them to account for between 26% and
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼ REZZAYO ® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 14:43:00 EEST | Press release
Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing allogeneic HSCT face prolonged periods of immunosuppression and routinely require extended antifungal prophylaxis,1 representing a setting where differentiated dosing, improved side effect profile, and reduced DDI is beneficial, and comparable efficacy is expected. The ReSPECT study met its primary endpoint for US Food and Drug Administration (FDA) and European Medicines
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom